Our data show miR-146a prevents intestinal inflammation and CRC by (1) limiting myeloid cell-mediated inflammatory IL-17 production and by (2) inhibiting tumorigenic IL-17R signaling in IECs (Fig. 7). Here, IL17A is linked to colorectal carcinoma.